10K-share sale by AC Immune (ACIU) CEO Andrea Pfeifer disclosed
AC Immune SA CEO Andrea Pfeifer sold 10,000 common shares in an open-market transaction on May 15, 2026, at a weighted average price of $2.7935 per share. Following this sale, Pfeifer directly holds 3,820,288 common shares, which includes 1,921,005 shares underlying restricted share units, and her spouse indirectly holds an additional 14,000 shares. This transaction was made under a 10b5-1 plan.
How this was made
The 30-second read
Why it matters
While insider sales can influence investor sentiment, they should be evaluated alongside company fundamentals and market conditions.
Market read
The insider sale is a noteworthy event but should be considered within the broader context of the company's performance and sector trends.
What to watch
The company's fundamentals, upcoming catalysts, or recent news releases may offset concerns raised by insider sales.
Background
Andrea Pfeifer, CEO of AC Immune, sold 10,000 shares at an average of $2.7935 on May 15, 2026. She holds a significant number of shares, including those underlying restricted share units.
Ticker impact
The insider sale by the CEO of AC Immune (ACIU) indicates a potential shift in insider sentiment, which may influence market perception.
Potential short-term downward pressure on ACIU stock due to insider selling, especially if accompanied by increased trading volume.
Insider sales can signal caution but are also influenced by personal financial planning. The sale's timing and volume relative to overall holdings suggest a moderate impact.
Market effects
The biotech sector may experience slight negative sentiment if multiple insider sales occur, but isolated events like this are unlikely to cause broad sector shifts.
Limited regional impact; primarily affects investors in the company's primary markets.
Minimal; the event is company-specific and unlikely to influence global markets.
Counterpoint
Insider sales do not necessarily indicate negative outlook; they may be for personal liquidity or diversification.
Key entities
- CompanyAC Immune SA
A biotech company focused on neurodegenerative diseases.
- ExecutiveAndrea Pfeifer
CEO of AC Immune, involved in the recent share sale.
